Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Common Equity (2020 - 2025)

Candel Therapeutics' Common Equity history spans 4 years, with the latest figure at $12.7 million for Q4 2023.

  • On a quarterly basis, Common Equity fell 73.29% to $12.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $12.7 million, a 73.29% decrease, with the full-year FY2023 number at $12.7 million, down 73.29% from a year prior.
  • Common Equity hit $12.7 million in Q4 2023 for Candel Therapeutics, down from $23.0 million in the prior quarter.
  • Over the last five years, Common Equity for CADL hit a ceiling of $64.1 million in Q4 2021 and a floor of -$43.2 million in Q2 2021.
  • Historically, Common Equity has averaged $22.4 million across 4 years, with a median of $30.8 million in 2023.
  • The widest YoY moves for Common Equity: up 525.13% in 2021, down 249.85% in 2021.
  • Tracing CADL's Common Equity over 4 years: stood at -$23.6 million in 2020, then surged by 372.21% to $64.1 million in 2021, then decreased by 25.61% to $47.7 million in 2022, then plummeted by 73.29% to $12.7 million in 2023.
  • Business Quant data shows Common Equity for CADL at $12.7 million in Q4 2023, $23.0 million in Q3 2023, and $30.8 million in Q2 2023.